NRx Pharmaceuticals

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge Read More